Crytalline derivative of 2-(5-Chlorothein-2-yl)-N-Ä(3S)-1(1S)-1methyl-2-morpholin-4-yl)-2-oxoethyl)-2-oxopyrrolidin-3-ylÜethensulfonamide

Crytalline derivative of 2-(5-Chlorothein-2-yl)-N-Ä(3S)-1(1S)-1methyl-2-morpholin-4-yl)-2-oxoethyl)-2-oxopyrrolidin-3-ylÜethensulfonamide

The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: DELL'ORCO, PHILIP, C, WATSON, NIGEL, S, SHAH, GITA, P, KELLY, HENRY, A, YOUNG, ROBERT, J
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.